Services of MTRC

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of September 22nd, we plan to work on 25 projects. Review the complete list of planned activities in this post.

MTRC has released a White Paper titled "Evidence Requirements for Non-IVD Diagnostic Technologies under NICE’s HealthTech Programme". This white paper reviews five assessments of non-IVD diagnostic technologies conducted under the former Diagnostics Assessment Programme (DAP) framework. Despite procedural changes, the case studies offer enduring insights into NICE’s evidence expectations and key factors influencing recommendation outcomes. These findings can help inform evidence generation strategies and support market access planning for similar technologies under the current HealthTech framework.

MTRC is pleased to present the 2025 EU Prioritization Matrix for Hospital Medical Devices - your annual, refresh-and-reuse guide to strategic market entry across Europe.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of September 08th, we plan to work on 25 projects. Review the complete list of planned activities in this post.

MTRC has released a White Paper titled "Reimbursement of Day Case Surgery Procedures in Europe". This white paper explores the reimbursement systems for day case (ambulatory) surgery in England, France, Germany, and Switzerland. With examples of several case studies, it highlights how reimbursement frameworks incentivize or hinder the adoption of day case procedures.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of August 25th, we plan to work on 23 projects. Review the complete list of planned activities in this post.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of August 11th, we plan to work on 16 projects. Review the complete list of planned activities in this post.

MTRC is pleased to present 2025 In-Vitro Diagnostic Tests Market Access Playbook - your annual, refresh‑and‑reuse roadmap to every EU reimbursement deadline.

MTRC has released a White Paper titled "Evidence Requirements for IVD Tests in NICE HealthTech Evaluations ". This white paper reviews five assessments of IVD diagnostic technologies conducted under NICE’s previous Diagnostics Assessment Programme (DAP) framework. While terminology and processes have evolved with the introduction of the HealthTech Evaluation Program, these case studies remain highly informative. They offer practical insights into NICE’s evidence expectations and common drivers of recommendation decisions, which continue to shape current evaluation approaches.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of July 28th, we plan to work on 16 projects. Review the complete list of planned activities in this post.

MTRC has released a White Paper titled "Clinical evidence requirements for the “Orderly Introduction of Medical Technologies” process in Sweden". This report provides an opportunity to learn about the evidence requirements of Sweden's Dental and Pharmaceutical Benefits Agency (TLV) and the Medical Technology Product (MTP) Council in relation to the national process of Orderly Introduction of medical technologies. White Paper outlines the key points and recommendations for the MedTech industry informed by three HTA reports with positive recommendations.

MTRC has released a White Paper titled "Evidence requirements for AI-based technologies in Europe." This Paper reviews evidence requirements for AI-based technologies as identified in five recent European HTA assessments, including urgent-care fracture detection (NICE, UK), hyperacute stroke imaging (NICE, UK), colonoscopic polyp detection (Danish Health Technology Council), and breast cancer screening programs (OSTEBA in Spain and SBU in Sweden).